Pfizer Q2 results beat; raises 2026 revenue outlook

Pfizer

04/08/2026 12:07

Overview
US drugmaker's Q2 revenue rose 3% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year 2026 revenue guidance midpoint by $500 mln to $61.5 bln

Outlook
Pfizer raises 2026 revenue guidance to $60.5-$62.5 bln, up $500 mln at midpoint
Company reaffirms 2026 adjusted diluted EPS guidance of $2.80-$3.00
Pfizer expects 2026 COVID-19 product revenues of about $4 bln, down from $5 bln

Result Drivers
LAUNCHED AND ACQUIRED PRODUCTS - 18% operational revenue growth from recently launched and acquired products, including Eliquis, Padcev, Vyndaqel family, and Lorbrena, per interim CFO Cecile Guegan
COVID-19 PRODUCT DECLINES - Revenue growth was partially offset by sharp declines in Paxlovid (down 95%) and Comirnaty (down 34%) due to lower COVID-19 infections and reduced government purchases
OPERATIONAL EFFICIENCY - Ongoing productivity initiatives and cost realignment programs supported results, according to management

Company press release: ID:nBw1CcZ6ma

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$15.03 bln
$14.41 bln (18 Analysts)
Q2 Adjusted EPS
Beat
$0.77
$0.68 (19 Analysts)
Q2 Loss Per Share
 
$0.04
 
Q2 Net Loss
 
$248 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 11 "strong buy" or "buy", 19 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Pfizer Inc is $28.00, about 11.9% above its August 3 closing price of $25.03
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)